Clinical trial · Observational
Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism
Microparticle's Procoagulant Activity to Identify Patients With Cancer and a High Risk for Venous Thrombosis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE). Risk assessment scores for VTE in cancer patients have been previously developed by the groups of Khorana and Vienna CATS. However, routine thromboprophylaxis for ambulatory cancer patients based on these scores is currently not recommended. In the investigators prospective, observational cohort study, the investigators aim to identify cancer patients at high risk for VTE based on clinical characteristics, coagulation biomarkers and the coagulant activity of tissue factor bearing microparticles.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Deep Venous Thrombosis | — | UNRESOLVED | — |
| Pulmonary Embolism | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- cancer patients
- description
- Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
Primary outcomes (1)
- measure
- venous thromboembolism
- timeFrame
- 6 months after enrollment
- description
- Objectively confirmed asymptomatic or symptomatic deep venous thrombosis or pulmonary embolism
Secondary outcomes (1)
- measure
- all-cause mortality
- timeFrame
- 6 months after enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago * Chemotherapy started no more than 3 months ago or within 7 days after enrollment * Aged 18 years or older * Written informed consent Exclusion Criteria: * Use of anticoagulants (heparin, vitamin K antagonists or direct oral anticoagulants) * Adjuvant chemotherapy (i.e. after surgery with curative intent)
References
Publications (2)
- DERIVEDBuijs JT, van Es N, Englisch C, Anijs RJS, Bosch FTM, van Vlijmen BJM, Mulder FI, Pabinger I, Ay C, Versteeg HH, Mohammed Y. Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer. Thromb Res. 2026 Mar;259:109612. doi: 10.1016/j.thromres.2026.109612. Epub 2026 Feb 6. PMID 41690262
- DERIVEDvan Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stepanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen PW, Buller HR. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017 Sep;102(9):1494-1501. doi: 10.3324/haematol.2017.169060. Epub 2017 May 26. PMID 28550192